We have been here before. The word spa has been quietly emptied of its meaning. Today it suggests a scented candle, a robe, an afternoon. For most of recorded history it meant something closer to the opposite: a prescription. The clearest evidence sits on the UNESCO World Heritage List. In 2021, eleven European towns across seven countries were inscribed as a single transnational property — The Great Spa Towns of Europe: Baden bei Wien (Austria); Spa (Belgium); Františkovy Lázně, Karlovy Vary and Mariánské Lázně (Czechia); Vichy (France); Bad Ems, Baden-Baden and Bad Kissingen (Germany); Montecatini Terme (Italy); and the City of Bath (United Kingdom). What earned them that status was not their beauty. It was that they represent, in UNESCO’s framing, a phenomenon with roots in antiquity that reached its highest expression from around 1700 to the 1930s — towns built around natural mineral springs that fused medical science, urban planning and social life into a single working system. They developed a distinct architecture to serve treatment: bathhouses, pump rooms, drinking halls, colonnades, and the kurhaus and kursaal — buildings dedicated explicitly to the cure. They employed professional medical practitioners skilled in spa medicine and balneology. They were, in UNESCO’s own description, the first towns in Europe designed around a medical purpose. Two things about that tradition matter for 2026. The first is that it was already holistic, and deliberately so. These towns married the mineral waters with exercise, diet, time in nature, and structured socialising. They were not water-cure clinics with amenities attached; the amenities were part of the protocol. The concept of leisure as an active ingredient in healing — not a reward for it — was baked in from the beginning. The second is that it was a genuine scientific enterprise, not just a fashionable one. Spa doctors, physicians and balneologists advanced medicine, geology and hydrology from these towns. They became centres of experimentation. That they also became centres of gambling, diplomacy, music and romance does not diminish this; it describes an ecosystem in which health, science, culture and commerce were entangled — which is precisely the situation we find ourselves in again today.
THE EASTERN LINEAGE IS OLDER STILL Japan’s hot-spring bathing goes back over two thousand years, with archaeological traces reaching into the Jōmon period. Its early associations were sacred — water as a purifying element in Shinto ritual, and springs where, in the oldest myths, gods healed their wounds. By the 7th century, emperors were visiting Arima and Dōgo. Springs such as Beppu, Yufuin and Arima served as tōji-ba — healing sites with religious and medicinal significance, used by the imperial family and Buddhist monks. The critical development is tōji — literally “hot water cure.” From the Sengoku period through the Edo period (1603–1868), onsen use expanded from the elite to samurai and townspeople, and tōji emerged as a formal therapeutic practice: staying at a single hot spring for a week or more, bathing several times daily at scheduled intervals, to restore health. It was matched to condition — sulphur springs for skin, carbonated springs for circulation, chloride springs for cold sensitivity. This is balneotherapy with a protocol, a duration and a dose. As one contemporary account puts it, the practice closely resembles the modern wellness retreat — with the difference that the historical version was measured in weeks, not a spare afternoon. The same instinct appears across Asia in different vocabularies. Chinese medicine developed yangsheng — the cultivation of life — organised around balance, prevention and daily regulation, expressed through herbal therapy, tui na massage, cupping and prescribed diets. Ayurveda, originating in India roughly three millennia ago, structured treatment around individual constitution — the three doshas — and personalised therapy to the person rather than the disease. Strip the metaphysics and a striking pattern remains. Every one of these traditions organised itself around prevention rather than cure, duration rather than intervention, and the whole person rather than the isolated symptom. They were, in modern language, healthspan systems. That is the thread. It never actually broke — it was interrupted by a century of acute medicine that was extraordinarily good at treating disease and largely uninterested in the years before disease arrives. What is happening in 2026 is not the invention of longevity culture. It is its return, with instruments.
WHERE THE WORLD STANDS IN 2026 The scale is no longer niche. The Global Wellness Institute — a research nonprofit, and the most methodologically reliable source in a field crowded with promotional estimates — put the global wellness economy at a record $6.8 trillion in 2024, with wellness real estate at $584 billion, the fastest-growing sector of all. The five largest national markets are the United States ($2.1 trillion), China ($950 billion), Germany ($281 billion), Japan ($262 billion) and the United Kingdom ($261 billion). Per-capita spending remains dramatically uneven: roughly $6,029 in North America against $1,876 in Europe and $471 in Asia. Each region is playing a different game. The United States leads the technology-enabled, outpatient, membership model. Human Longevity Inc., Fountain Life, Prenuvo, Function Health and Next Health deliver whole-body diagnostics on a same-day or annual-subscription basis. Pricing typically runs from around $15,000 to $21,500 a year at the premium end. It is also where the capital sits: Jeff Bezos backed Altos Labs at a reported $3 billion, Larry Ellison has committed $430 million to aging research, and Sam Altman put $180 million into Retro Biosciences. Europe retains the residential tradition — direct descendants of the Kur. Lanserhof, Clinique La Prairie, Chenot Palace, SHA Wellness and Buchinger Wilhelmi bundle accommodation, diagnostics and treatment into multi-day or multi-week stays, typically €5,000–25,000 for one to two weeks, with ultra-premium Swiss programmes exceeding €50,000. Germany leads in fasting and integrative medicine; Spain has emerged as the strongest value tier. The most significant European development is not clinical but structural: reported moves toward insurance-reimbursable preventive longevity assessment — the field’s real legitimacy test. Asia is the fastest-growing region and the most bifurcated. Japan combines the world’s longest life expectancy — approximately 84.5 years, the highest in the OECD — with genuine leadership in regenerative medicine; in February 2025 Japanese regulators endorsed the first iPS-cell-based therapies, for severe heart failure and Parkinson’s disease. China is expanding aggressively into gene-based and regenerative research, and hosts the region’s only cryonics facility. Clinique La Prairie has opened in Anji, China, with projects underway in Phuket, Bangkok, Taipei and Saudi Arabia. Singapore is growing fast in precision diagnostics. The research has produced its own landmark. In September 2025, a team led by Manel Esteller at the Josep Carreras Leukaemia Research Institute published in Cell Reports Medicine the most complete biological portrait ever assembled of a supercentenarian: María Branyas Morera, the world’s oldest verified person until her death in 2024 at 117. Her genome, epigenome, proteome, metabolome, transcriptome and microbiome were mapped together. The finding that matters: aging and disease can decouple. Multiple biological clocks placed her more than 23 years younger than her chronological age, alongside low inflammation, a youthful microbiome and protective genetic variants — while she simultaneously carried very short telomeres and clonal hematopoiesis. She was, biologically, both very old and very well. The researchers are careful to note that one person cannot yield a universal formula. But the principle beneath the entire modern field is now demonstrated in a human being: you can be old without being ill.
THE SCIENCE: WHAT AGING ACTUALLY IS If the industry has a scientific spine, it is a single paper — “Hallmarks of Aging: An Expanding Universe,” by Carlos López-Otín and colleagues, published in Cell in 2023, updating their landmark 2013 framework from nine hallmarks to twelve. The twelve are: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis. They are not a flat list. They sort into three tiers by causal role. Primary — the causes of damage. Genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled autophagy. Molecular damage that accumulates with time. Unambiguously harmful, with no beneficial version. DNA acquires errors; the protective caps on chromosomes shorten; the epigenetic marks instructing each cell which genes to express drift out of pattern; protein quality control fails; and the cell’s recycling system slows. Antagonistic — the responses gone wrong. Deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence. This is the conceptually richest tier: these are the body’s responses to damage, protective in youth and destructive when chronic. Cellular senescence protects against cancer and aids wound healing in a young body; with age it rises beyond physiological levels and begins to impair the organism. Most promising drugs act here — which is exactly why they are double-edged. Integrative — the system-level consequences. Stem cell exhaustion, altered intercellular communication, chronic inflammation, dysbiosis. These emerge when accumulated damage overwhelms repair capacity. This is the tier one actually experiences as aging: frailty, slow healing, cognitive decline, immune weakness. It is also the tier the Branyas data pointed to — her exceptional health tracked with low inflammation and a youthful microbiome even as she carried primary-tier damage. Damage in the upper tier drives dysfunction below it, and the hallmarks are interconnected, reinforcing one another into a cascade.
WHY THIS FRAMEWORK DISSOLVES MOST OF THE HYPE The single most useful consequence of the hallmarks model is that it explains why there is no longevity pill. Aging is not one mechanism failing; it is at least twelve interconnected processes, which is why the field’s serious researchers advocate multi-modal approaches. A drug that targets one node in one tier lets the interconnected cascade route around it. It also explains, in precise mechanistic language, why the unglamorous fundamentals outperform the expensive interventions. Exercise improves mitochondrial function and quality, lowers chronic inflammation, improves insulin signalling and nutrient-sensing, and supports stem-cell activity — four hallmarks across three tiers, from one intervention. Caloric moderation and fasting act directly on nutrient-sensing (the mTOR and AMPK pathways — the same targets rapamycin and metformin pursue pharmacologically) and switch autophagy back on. Sleep regulates inflammation and supports proteostasis. Social connection acts on intercellular communication and inflammation. This is now being confirmed at molecular resolution rather than merely inferred: 2025 multi-tissue work is building an atlas showing that lifestyle interventions including dietary restriction and smoking cessation measurably shift ageing-linked molecular features — evidence for the malleability of aging biology itself. The human outcome data is correspondingly lopsided. A Cochrane overview covering 187 randomised controlled trials and 27,671 participants found a 13% reduction in mortality risk from exercise. A study of 226,000 adults associated just 1,000 additional steps per day with a 15% reduction in all-cause mortality. Resistance training independently reduces all-cause, cardiovascular and cancer mortality. No pharmaceutical intervention aimed at healthy aging has matched that. The flagship human rapamycin longevity trial, PEARL, missed its primary endpoint. Metformin showed no benefit in sarcopenic older adults, and its definitive trial has not launched. NAD+ precursors reliably raise blood NAD+ and, in the best-designed test, still failed to improve metabolic health. Senolytics have proven they clear senescent cells in humans within days — a genuine achievement — but have not yet proven that doing so makes people healthier. The one significant exception is the GLP-1 receptor agonist class, where the SELECT trial in 17,604 patients with obesity and cardiovascular disease showed a 20% reduction in major cardiovascular events — proven benefit, though in a specific population and with no approved anti-aging indication.
THE HONEST CAVEAT The hallmarks framework is the best scaffold the field has, not settled law. It has been criticised as insufficient as a causative paradigm of aging, and the underlying data is drawn mostly from humans and a handful of model organisms. An active reframing — visible in the 2026 Berlin congress agenda — proposes treating aging less as a set of discrete mechanisms and more as a system-level loss of coordination between metabolism, immunity, mitochondria and the microbiome. Which, it is worth noticing, is remarkably close to what the balneologists of Baden-Baden and the tōji practitioners of Beppu were assuming all along.